ITM Isotopen Technologien München AG was founded in 2004 and is a privately held group of radiopharmaceutical companies, dedicated to the development and proprietary production of novel radiopharmaceuticals and radiomedical devices. Today, more than 50 highly trained employees bring in their profound knowledge and experience of meanwhile more than a decade, focusing on next generation radioisotope sourcing and processing for the treatment of numerous serious oncological diseases. The ITM Group develops and commercializes its unique product portfolio and innovative pipeline also by reaching global strategic alliances with leading partners in the pharmaceutical industry.
The ITM Group’s innovative platform technologies also enable manufacturers of conventional therapeutic agents not only to improve the efficacy of their candidates but also to benefit from ITM Group’s exceptionally advanced GMP infrastructure and global logistics network. The company's main goal is to improve the wellbeing and quality of life of patients by bringing a new generation of targeted radiopharmaceuticals for theranostics to the market.